Group 1: Financial Performance - Eton Pharmaceuticals reported a quarterly loss of $0.02 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.09 per share a year ago [1] - The company posted revenues of $11.65 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 9.05%, and up from $7.31 million year-over-year [2] - The current consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $14.31 million, and for the current fiscal year, it is $0.50 on revenues of $84.16 million [7] Group 2: Market Performance and Outlook - Eton Pharmaceuticals shares have increased by approximately 14.8% since the beginning of the year, while the S&P 500 has declined by 3.5% [3] - The company has a favorable estimate revisions trend, resulting in a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] - The Medical - Biomedical and Genetics industry is currently in the top 28% of Zacks industries, suggesting a positive outlook for stocks within this sector [8]
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates